Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?
Authors:
- Martin MetzMMMartin Metz
- Marcus MaurerMMMarcus Maurer
- 1 January 2021
- journal article
- review article
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 5 (01) , 89-95
Abstract
In chronic spontaneous urticaria (CSU), itchy wheals, angioedema, or both occur regularly, often daily, and for years. An effective therapy for CSU aims at achieving complete symptom control. The current guideline for the management of CSU patients recommends non-sedative anthistamines in standard or up to 4-fold higher dosages as 1 and 2 line treatment. For most CSU patients this treatment is not sufficient; for them, the anti-IgE antibody omalizumab is the therapy of choice. Although good to very good symptom control can be achieved in most cases, there are many patients with insufficient response. For these patients, but also as an alternative to therapy with omalizumab, numerous other biologicals are currently under development. In this review, we provide an overview of possible future biologic therapies for chronic urticaria.Keywords
This publication has 45 references indexed in Scilit:
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaNew England Journal of Medicine, 2013
- Chronic idiopathic urticaria (CIU) is no longer idiopathic: time for an updateBritish Journal of Dermatology, 2012
- Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1Allergy, 2010
- Chronic idiopathic urticaria: prevalence and clinical courseThe Journal of Dermatology, 2007
- Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300aJournal of Allergy and Clinical Immunology, 2006
- Serological detection of eotaxin, IL-4, IL-13, IFN-γ, MIP-1α, TARC and IP-10 in chronic autoimmune urticaria and chronic idiopathic urticariaJournal of Dermatological Science, 2004
- Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patientsAllergy, 2004
- A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticariaJournal of Allergy and Clinical Immunology, 2002
- An Overview of Chronic UrticariaClinical Reviews in Allergy & Immunology, 2002
- Histamine release in intact human skin by monocyte chemoattractant factor-1, RANTES, macrophage inflammatory protein-1α, stem cell factor, anti-IgE, and codeine as determined by an ex vivo skin microdialysis techniqueJournal of Allergy and Clinical Immunology, 1996